Pcovery ApS is developing new and proprietary drugs for the treatment of human fungal infections, by addressing a novel fungal drug-target, which plays a critical role in fungal cell physiology and growth. Most fungi are not pathogenic to plants, animals or humans. However, a few fungal species can cause devastating infections in man. The most common causes of opportunistic infections are traditionally Candida albicans, Cryptococcus neoformans, Aspergillus, and Fusarium species causing serious diseases in humans, with even fatal outcome in man, in both healthy and immunocompromised individuals.
Although the present market presents a range of antifungal antibiotics for clinical use, the current management of fungal infections is restricted by drug safety, drug resistance and drug effectiveness. Accordingly there is a clear need for novel, safe and broad spectrum antifungals, as researched by Pcovery. Pcovery is based in Copenhagen, Denmark.
Year of investment: 2014; BIVF Board Representative: Ilka Wicke